SDX 7320Alternative Names: MetAP2 inhibitor - SynDevRx; Methionine aminopeptidase type II - SynDevRx; SDX-7320
Latest Information Update: 27 Apr 2016
At a glance
- Originator SynDevRx, Inc
- Mechanism of Action DNA synthesis inhibitors; Methionine aminopeptidase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Feb 2016 Phase-I clinical trials in Solid tumours (Late-stage disease, Refractory metastatic disease) in USA (SC) (NCT02743637)
- 25 May 2011 SynDevRX files for patent protection for SDX 7320 in USA